DCexos could be modified to express TNF, FasL, and TRAIL to target tumor cells directly and induce tumor cell apoptosis, and DCexos could be engineered to transfer miRNAs, cytokines, and chemokines, mRNAs that encode relevant neoantigens or regulatory proteins to modulate gene functions in targeted immune cells or cancer cells. This evidence concerns the gene TNFSF10 and cancer.